Can hepatitis C virus infection be eradicated in people who inject drugs?
about
Injecting drug use: A vector for the introduction of new hepatitis C virus genotypesThe hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for preventionMutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infectionsInfluence of host resistance on viral adaptation: hepatitis C virus as a case studyInactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugsAccess to healthcare insurance and healthcare services among syringe exchange program clients in Massachusetts: qualitative findings from health navigators with the iDU ("I do") Care Collaborative.Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012.Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitisHepatitis C virus infection: from margin to center in rhode island and beyond.Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013.Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013.The common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perceptionCan HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs?Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential.Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence.HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan.Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication.Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.Direct-acting antiviral agents for HCV infection affecting people who inject drugs.Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs.Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?Real-world challenges for hepatitis C virus medications: a critical overview.Social determinants and risk behaviors associated with prevalent Hepatitis C and HIV/HCV co-infection among male injection drug users in Nepal.HCV avidity as a tool for detection of recent HCV infection: sensitivity depends on HCV genotype.High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?Hepatitis C infection and other drug-related harms among inpatients who injected drugs in Turkey.Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV InfectionAddressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care.Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first?Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cellsThe 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era.Global Mortality Burden of Cirrhosis and Liver Cancer Attributable to Injection Drug Use, 1990-2016: An Age-Period-Cohort and Spatial Autocorrelation Analysis.Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis.Hepatitis C virus prevention and care for drug injectors: the French approach
P2860
Q26781991-92694D01-7766-4CBC-AD1C-99F1F733D8B6Q26801456-716BF57D-2B38-4C23-9B1C-090BA16F7E32Q28086907-5A931230-38DA-48D1-8A13-81E8CA2D76E7Q28087595-52AEF20A-79B0-464B-9F64-1DEDA0FDB11AQ30369227-2581F038-EE53-4782-B4AC-04E74539E4E4Q33706376-DCEE3B6B-6B49-4404-A113-8E1F5A6B5AB1Q33711886-EC141AF6-2D35-44E6-855C-55DADE6580F2Q34260671-94D9B60C-5C61-4A97-AF52-14B14867D258Q35219812-22406E9A-3417-446A-8D36-B853143468B9Q35628314-98ABCA9F-5C37-4DF1-B43D-96905BFBFAB6Q35690302-A3873B40-E4CA-4A8D-B31C-3E605F37BBC7Q35770129-B4F199F7-0A4F-463B-9664-257240DF0509Q35998417-DECE0F04-D10E-40F1-ACAD-84FE8817AC8EQ36079786-ACA56285-E2E5-4D5B-B757-E79EF17E7305Q36090175-3A228B05-6D49-4FC6-B84D-B6EC6EBE8B80Q36192804-EE1934F7-D31B-4C0C-A534-C9F3E123E825Q36319803-577EAC4F-0E76-4848-B14D-35423C117CC9Q36506119-C8C5BC2F-81F2-4242-B8A0-8F4CD0B9117FQ36997093-31F7BE05-4AAD-4BB3-92F0-0CB2A6900DD6Q38380343-E0B6AFBC-9215-4AA6-A634-DBB03CC35BBBQ38381584-8F189A1F-2F2D-49A7-ABCE-5D3A0DF354DBQ38613271-C82DB68B-072C-4B00-8991-87BB81433DC6Q38661825-DA119EC1-D5CF-4325-996E-87984DAC6E5FQ38710078-8178DC6B-7990-437A-BE6C-067B023F3C5CQ38746105-3D052717-3572-4C03-A98E-B4C8C756D7DCQ39326974-5A7AB326-2EC6-4AE2-92FA-9B5B0230BAB0Q40054669-BE43CA0F-9720-4F45-8ECF-756D9483AC3BQ40069643-17FF9669-CE9B-4A1F-A2BF-D4CDCB388F88Q40082158-A2ECD5AF-54CE-40A7-A404-9E543965B7A8Q40364008-5D954839-75E9-414F-8059-28DEA905D5DFQ40420693-B668A4B2-8F49-402D-91A0-0E13AD1ABB2EQ40832940-1FA6E03C-BDB2-49E2-B994-2BCFB3563BABQ41496602-72AB85A5-B91F-4C34-8935-8B7AF50C707AQ41546485-BD455D88-8032-423D-9D65-956D79A48BB6Q41672541-D10257FE-1DC5-4A25-B906-A6B30CB7A8CFQ41893704-5BAFA7AA-AA09-4026-A67E-2A279C9CF863Q42955909-4523A725-8094-4EE6-BAF3-56E59E629388Q47800804-FDCAE766-E1D8-4C36-B811-B31438987107Q53281101-6780413C-5F69-469F-ADF7-31A33CC21742Q57144432-F16B2FF6-9B37-4B48-9D50-71A93BC0E614
P2860
Can hepatitis C virus infection be eradicated in people who inject drugs?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Can hepatitis C virus infection be eradicated in people who inject drugs?
@en
type
label
Can hepatitis C virus infection be eradicated in people who inject drugs?
@en
prefLabel
Can hepatitis C virus infection be eradicated in people who inject drugs?
@en
P1433
P1476
Can hepatitis C virus infection be eradicated in people who inject drugs?
@en
P2093
Gregory J Dore
Jason Grebely
P356
10.1016/J.ANTIVIRAL.2014.01.002
P577
2014-01-24T00:00:00Z